KR20160093024A - 눈 질환의 치료에 사용하기 위한 cetp 조절제 - Google Patents

눈 질환의 치료에 사용하기 위한 cetp 조절제 Download PDF

Info

Publication number
KR20160093024A
KR20160093024A KR1020167016160A KR20167016160A KR20160093024A KR 20160093024 A KR20160093024 A KR 20160093024A KR 1020167016160 A KR1020167016160 A KR 1020167016160A KR 20167016160 A KR20167016160 A KR 20167016160A KR 20160093024 A KR20160093024 A KR 20160093024A
Authority
KR
South Korea
Prior art keywords
cetp
amd
disease
modulator
lutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167016160A
Other languages
English (en)
Korean (ko)
Inventor
에블린 샤푸트
에릭 제이 니소르
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20160093024A publication Critical patent/KR20160093024A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167016160A 2013-12-19 2014-12-16 눈 질환의 치료에 사용하기 위한 cetp 조절제 Withdrawn KR20160093024A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198668.9 2013-12-19
EP13198668 2013-12-19
PCT/EP2014/077855 WO2015091410A1 (en) 2013-12-19 2014-12-16 Cetp modulator for use in the treatment of eye disease

Publications (1)

Publication Number Publication Date
KR20160093024A true KR20160093024A (ko) 2016-08-05

Family

ID=49880487

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167016160A Withdrawn KR20160093024A (ko) 2013-12-19 2014-12-16 눈 질환의 치료에 사용하기 위한 cetp 조절제

Country Status (11)

Country Link
US (2) US20160287537A1 (https=)
EP (2) EP3082784A1 (https=)
JP (1) JP6539661B2 (https=)
KR (1) KR20160093024A (https=)
CN (1) CN105792820A (https=)
BR (1) BR112016013923A2 (https=)
CA (1) CA2924401A1 (https=)
HK (1) HK1223827A1 (https=)
MX (1) MX2016005505A (https=)
RU (1) RU2016127357A (https=)
WO (1) WO2015091410A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2978859T1 (sl) 2013-03-27 2018-10-30 F. Hoffmann-La Roche Ag Genetski označevalci za napovedovanje odzivnosti na terapijo
MX384679B (es) 2014-07-30 2025-03-14 Hoffmann La Roche Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
WO2025093129A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE60318390T2 (de) 2002-01-30 2008-12-18 Dsm Ip Assets B.V. Lutein/zeaxanthin gegen blendung
PT1603553E (pt) 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
US8212063B2 (en) 2006-05-10 2012-07-03 Omniactive Health Technologies Limited Xanthophyll composition containing trans, meso-zeaxanthin, trans, R, R-zeaxanthin and trans, R, R-lutein useful for nutrition and health care and a process for its preparation
EP1935867A1 (en) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
WO2009129859A1 (en) 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
WO2010074940A1 (en) * 2008-12-23 2010-07-01 Alcon Research, Ltd. Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process
CN103200935A (zh) 2010-11-04 2013-07-10 霍夫曼-拉罗奇有限公司 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物
ES2828479T3 (es) * 2011-01-25 2021-05-26 Nestle Sa Métodos y composiciones para tratar, reducir o prevenir el deterioro del sistema visual de los animales
US20120301439A1 (en) * 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization
CA2879597C (en) * 2012-08-21 2021-01-12 Opko Pharmaceuticals, Llc Ophthalmic liposome formulations for treating posterior segment disease

Also Published As

Publication number Publication date
MX2016005505A (es) 2016-07-22
CN105792820A (zh) 2016-07-20
EP3524238A1 (en) 2019-08-14
US20190224147A1 (en) 2019-07-25
BR112016013923A2 (pt) 2017-08-08
CA2924401A1 (en) 2015-06-25
WO2015091410A1 (en) 2015-06-25
JP2017500340A (ja) 2017-01-05
JP6539661B2 (ja) 2019-07-03
RU2016127357A (ru) 2018-01-24
HK1223827A1 (zh) 2017-08-11
US20160287537A1 (en) 2016-10-06
EP3082784A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
US20190224147A1 (en) Cetp modulator for use in the treatement of eye disease
CN103998035B (zh) 包含格列酮和nrf2激活剂的药物组合物
EP2277516A1 (en) Retinyl derivatives for treating ophtalmic conditions
WO2010087306A1 (ja) 抗神経変性疾患剤
JP7248836B2 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
CN101252924A (zh) 通过血清视黄醇、血清视黄醇结合蛋白(rbp)和/或血清视黄醇-rbp调节治疗眼部疾病的方法和组合物
WO2009124294A2 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
KR20180011777A (ko) 망막 색소 상피 세포를 보호하기 위한 노르빅신 함유 조성물
Gao et al. Retinal-chitosan conjugates effectively deliver active chromophores to retinal photoreceptor cells in blind mice and dogs
US20100323992A1 (en) Pharmaceutical compositions for preventing and treating eye pathologies
US20170035708A1 (en) Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide for the treatment of eye diseases
JP2023062085A (ja) 黄斑変性予防又は治療用組成物
JPWO2007037188A1 (ja) 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
US11717513B2 (en) Mirabegron for the treatment of retinal diseases
JP6372940B2 (ja) 網膜色素変性症（ｒｐ）を治療するための薬剤の製造のための化合物の使用
US20170246176A1 (en) Phacosclerosis inhibitor
Abraham et al. Age-related macular degeneration and its treatment options
JP2025522938A (ja) 網膜／認知機能およびアテローム性動脈硬化症を改善するための超長鎖ポリ不飽和脂肪酸（ｖｌｃｐｕｆａ）
WO2021055419A1 (en) Compositions for improving eye health and methods of making and using thereof
EA016869B1 (ru) КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И АГОНИСТОВ PPARα

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160617

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid